Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
Saved in:
| Title: | Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. |
|---|---|
| Authors: | Porter ML; Department of Dermatology, Harvard Medical School, Boston, MA, USA.; Beth Israel Deaconess Medical Center, Boston, MA, USA., Martorell A; Inflammatory Diseases Unit, Department of Dermatology, Venereology and Surgery, Hospital de Manises, Valencia, Spain., Sayed CJ; Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Bechara FG; ICH - International Center for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany., Lev-Tov H; Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA., Hsiao JL; Department of Dermatology, University of Southern California, Los Angeles, CA, USA., Frew JW; Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia.; Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia.; School of Clinical Medicine, University of New South Wales Sydney, Kensington, New South Wales, Australia., Reguiaï Z; Department of Dermatology, Polyclinique Courlancy-Bezannes, Reims-Bezannes, France., Gooderham MJ; Probity Medical Research, Waterloo, Ontario, Canada.; SKiN Centre for Dermatology, Peterborough, Ontario, Canada.; Queen's University, Kingston, Ontario, Canada., Goldfarb N; Departments of Dermatology and Medicine, University of Minnesota, Minneapolis, MN, USA.; Department of Dermatology, University of Minnesota Physicians, Minneapolis, MN, USA., van der Zee HH; Department of Dermatology, Erasmus Medical Center, Rotterdam, Netherlands., Del Marmol V; Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium., Marzano AV; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy., Ehst BD; Oregon Medical Research Center, Portland, OR, USA., Ackerman LS; USA Medical Dermatology Specialists, US Dermatology Partners, Phoenix, AZ, USA., Hayama K; Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Itabashi City, Tokyo, Japan., Tian C; Incyte Corporation, Wilmington, DE, USA., Kelley J; Incyte Corporation, Wilmington, DE, USA., Zhen H; Incyte Corporation, Wilmington, DE, USA., Kirby JS; Incyte Corporation, Wilmington, DE, USA., Brown K; Incyte Corporation, Wilmington, DE, USA., Santos LL; Incyte Corporation, Wilmington, DE, USA., Zouboulis CC; Department of Dermatology, Venereology, and Immunology, Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany. christos.zouboulis@mhb-fontane.de. |
| Source: | Nature medicine [Nat Med] 2026 Jul 23. Date of Electronic Publication: 2026 Jul 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
